10-Q Filing

MERCK & CO., INC. CIK: 310158 Q2 2023

Filing Information

Form Type	10-Q
Accession Number	`0001628280-23-027770`
Period End Date	20230630
Filing Date	20230807
Fiscal Year	2023
Fiscal Period	Q2
XBRL Instance	mrk-20230630_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 80 Income Statement 56 Cash Flow Statement 70 Comprehensive Income 24

Balance Sheet 80 line items

Line Item	Tag	Value	Unit	Period
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$86.00M	USD	Point-in-time
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$72.00M	USD	Point-in-time
Inventories classified in Other assets	`InventoryNoncurrent`	$2.94B	USD	Point-in-time
Inventories classified in Other assets	`InventoryNoncurrent`	$3.22B	USD	Point-in-time
Accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$17.98B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$5.66B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$12.69B	USD	Point-in-time
Accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$18.43B	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Short-term investments	`ShortTermInvestments`	$498.00M	USD	Point-in-time
Short-term investments	`ShortTermInvestments`	$718.00M	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $86 in 2023 and $72 in 2022)	`AccountsReceivableNetCurrent`	$11.03B	USD	Point-in-time
Common stock, authorized (shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Common stock, authorized (shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $86 in 2023 and $72 in 2022)	`AccountsReceivableNetCurrent`	$9.45B	USD	Point-in-time
Common stock, issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Common stock, issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Inventories (excludes inventories of $3,220 in 2023 and $2,938 in 2022 classified in Other assets - see Note 7)	`InventoryNet`	$5.93B	USD	Point-in-time
Inventories (excludes inventories of $3,220 in 2023 and $2,938 in 2022 classified in Other assets - see Note 7)	`InventoryNet`	$5.91B	USD	Point-in-time
Treasury stock (in shares)	`TreasuryStockCommonShares`	1.04B	shares	Point-in-time
Treasury stock (in shares)	`TreasuryStockCommonShares`	1.04B	shares	Point-in-time
Other current assets	`DeferredIncomeTaxesAndOtherAssetsCurrent`	$6.64B	USD	Point-in-time
Other current assets	`DeferredIncomeTaxesAndOtherAssetsCurrent`	$7.17B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$35.72B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$29.98B	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$1.21B	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$1.01B	USD	Point-in-time
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,432 in 2023 and $17,985 in 2022	`PropertyPlantAndEquipmentNet`	$22.23B	USD	Point-in-time
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,432 in 2023 and $17,985 in 2022	`PropertyPlantAndEquipmentNet`	$21.42B	USD	Point-in-time
Goodwill	`Goodwill`	$21.20B	USD	Point-in-time
Goodwill	`Goodwill`	$21.20B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$19.66B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$20.27B	USD	Point-in-time
Other Assets	`DeferredIncomeTaxesAndOtherAssetsNoncurrent`	$9.53B	USD	Point-in-time
Other Assets	`DeferredIncomeTaxesAndOtherAssetsNoncurrent`	$10.19B	USD	Point-in-time
Total Assets	`Assets`	$109.16B	USD	Point-in-time
Total Assets	`Assets`	$104.47B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$1.95B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$2.84B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$4.26B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$3.44B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$14.16B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$13.75B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$1.99B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$1.49B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.88B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.88B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$23.39B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$24.24B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$28.75B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$34.07B	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$1.79B	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$996.00M	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$7.26B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$8.32B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2023 and 2022	`CommonStockValue`	$1.79B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2023 and 2022	`CommonStockValue`	$1.79B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$44.38B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$44.22B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$54.20B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$61.08B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-4.90B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-4.77B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$95.31B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$102.48B	USD	Point-in-time
Less treasury stock, at cost: 1,037,678,033 shares in 2023 and 1,039,269,638 shares in 2022	`TreasuryStockCommonValue`	$56.49B	USD	Point-in-time
Less treasury stock, at cost: 1,037,678,033 shares in 2023 and 1,039,269,638 shares in 2022	`TreasuryStockCommonValue`	$56.61B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$38.69B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$45.99B	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$67.00M	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$49.00M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$46.91B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$43.32B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$38.26B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$38.74B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$40.95B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$46.06B	USD	Point-in-time
Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$104.47B	USD	Point-in-time
Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$109.16B	USD	Point-in-time

Income Statement 56 line items

Line Item	Tag	Value	Unit	Period
Sales	`Revenues`	$15.04B	USD	1 Quarter
Sales	`Revenues`	$14.59B	USD	1 Quarter
Sales	`Revenues`	$30.49B	USD	2 Qtrs
Sales	`Revenues`	$29.52B	USD	2 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$9.60B	USD	2 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$4.22B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$7.95B	USD	2 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$4.02B	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$5.18B	USD	2 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$2.51B	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$2.70B	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$4.83B	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$2.80B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$5.37B	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$13.32B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$17.60B	USD	2 Qtrs
Restructuring costs	`RestructuringCharges`	$194.00M	USD	2 Qtrs
Restructuring costs	`RestructuringCharges`	$142.00M	USD	1 Quarter
Restructuring costs	`RestructuringCharges`	$218.00M	USD	2 Qtrs
Restructuring costs	`RestructuringCharges`	$151.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-172.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-259.00M	USD	2 Qtrs
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-1.15B	USD	2 Qtrs
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-438.00M	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$20.37B	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$21.15B	USD	2 Qtrs
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$10.11B	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$31.21B	USD	2 Qtrs
(Loss) Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-5.33B	USD	1 Quarter
(Loss) Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$4.49B	USD	1 Quarter
(Loss) Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$9.35B	USD	2 Qtrs
(Loss) Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-1.69B	USD	2 Qtrs
Income Tax Provision	`IncomeTaxExpenseBenefit`	$1.46B	USD	2 Qtrs
Income Tax Provision	`IncomeTaxExpenseBenefit`	$538.00M	USD	1 Quarter
Income Tax Provision	`IncomeTaxExpenseBenefit`	$1.09B	USD	2 Qtrs
Income Tax Provision	`IncomeTaxExpenseBenefit`	$637.00M	USD	1 Quarter
Net (Loss) Income	`ProfitLoss`	$8.26B	USD	2 Qtrs
Net (Loss) Income	`ProfitLoss`	$-5.97B	USD	1 Quarter
Net (Loss) Income	`ProfitLoss`	$-3.15B	USD	2 Qtrs
Net (Loss) Income	`ProfitLoss`	$3.95B	USD	1 Quarter
Less: Net Income Attributable to Noncontrolling Interests	`IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity`	$2.00M	USD	2 Qtrs
Less: Net Income Attributable to Noncontrolling Interests	`IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity`	$5.00M	USD	1 Quarter
Less: Net Income Attributable to Noncontrolling Interests	`IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity`	$3.00M	USD	1 Quarter
Less: Net Income Attributable to Noncontrolling Interests	`IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity`	$7.00M	USD	2 Qtrs
Net (Loss) Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$-5.97B	USD	1 Quarter
Net (Loss) Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$8.25B	USD	2 Qtrs
Net (Loss) Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$3.94B	USD	1 Quarter
Net (Loss) Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$-3.15B	USD	2 Qtrs
Basic (Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$3.26	USD	2 Qtrs
Basic (Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$1.56	USD	1 Quarter
Basic (Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$-2.35	USD	1 Quarter
Basic (Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$-1.24	USD	2 Qtrs
(Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$1.55	USD	1 Quarter
(Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$-1.24	USD	2 Qtrs
(Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$3.25	USD	2 Qtrs
(Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$-2.35	USD	1 Quarter

Cash Flow Statement 70 line items

Line Item	Tag	Value	Unit	Period
Restricted cash	`RestrictedCashAndCashEquivalents`	$52.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$79.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$71.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$78.00M	USD	Point-in-time
Net (loss) income	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$8.26B	USD	2 Qtrs
Net (loss) income	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$-3.15B	USD	2 Qtrs
Amortization	`AdjustmentForAmortization`	$1.16B	USD	2 Qtrs
Amortization	`AdjustmentForAmortization`	$1.02B	USD	2 Qtrs
Depreciation	`Depreciation`	$874.00M	USD	2 Qtrs
Depreciation	`Depreciation`	$895.00M	USD	2 Qtrs
(Income) loss from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$274.00M	USD	2 Qtrs
(Income) loss from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$-991.00M	USD	2 Qtrs
(Income) loss from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$-175.00M	USD	1 Quarter
(Income) loss from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$-284.00M	USD	1 Quarter
Charge for the acquisition of Prometheus Biosciences, Inc.	`ResearchAndDevelopmentAssetAcquisitionOtherThanThroughBusinessCombinationWriteOffAssetAcquisitionTwo`	$10.22B	USD	2 Qtrs
Charge for the acquisition of Prometheus Biosciences, Inc.	`ResearchAndDevelopmentAssetAcquisitionOtherThanThroughBusinessCombinationWriteOffAssetAcquisitionTwo`	-	USD	2 Qtrs
Charge for the acquisition of Imago BioSciences, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff`	-	USD	2 Qtrs
Charge for the acquisition of Imago BioSciences, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff`	$1.19B	USD	2 Qtrs
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-600.00M	USD	2 Qtrs
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-632.00M	USD	2 Qtrs
Share-based compensation	`ShareBasedCompensation`	$257.00M	USD	2 Qtrs
Share-based compensation	`ShareBasedCompensation`	$314.00M	USD	2 Qtrs
Other	`OtherNoncashIncomeExpense`	$-799.00M	USD	2 Qtrs
Other	`OtherNoncashIncomeExpense`	$-5.00M	USD	2 Qtrs
Net changes in assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$4.53B	USD	2 Qtrs
Net changes in assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$2.70B	USD	2 Qtrs
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$5.04B	USD	2 Qtrs
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$9.06B	USD	2 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$2.11B	USD	2 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$1.97B	USD	2 Qtrs
Purchases of securities and other investments	`PaymentsToAcquireMarketableSecurities`	$587.00M	USD	2 Qtrs
Purchases of securities and other investments	`PaymentsToAcquireMarketableSecurities`	$705.00M	USD	2 Qtrs
Proceeds from sales of securities and other investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$374.00M	USD	2 Qtrs
Proceeds from sales of securities and other investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$785.00M	USD	2 Qtrs
Acquisition of Prometheus Biosciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	-	USD	2 Qtrs
Acquisition of Prometheus Biosciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$10.71B	USD	2 Qtrs
Acquisition of Imago BioSciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	$1.33B	USD	2 Qtrs
Acquisition of Imago BioSciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	-	USD	2 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-4.00M	USD	2 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-194.00M	USD	2 Qtrs
Net Cash Used in Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-13.80B	USD	2 Qtrs
Net Cash Used in Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-2.25B	USD	2 Qtrs
Net change in short-term borrowings	`ProceedsFromRepaymentsOfShortTermDebt`	-	USD	2 Qtrs
Net change in short-term borrowings	`ProceedsFromRepaymentsOfShortTermDebt`	$1.94B	USD	2 Qtrs
Proceeds from issuance of debt	`ProceedsFromIssuanceOfLongTermDebt`	-	USD	2 Qtrs
Proceeds from issuance of debt	`ProceedsFromIssuanceOfLongTermDebt`	$5.95B	USD	2 Qtrs
Payments on debt	`RepaymentsOfLongTermDebt`	$1.75B	USD	2 Qtrs
Payments on debt	`RepaymentsOfLongTermDebt`	$1.25B	USD	2 Qtrs
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$487.00M	USD	2 Qtrs
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	-	USD	2 Qtrs
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$3.52B	USD	2 Qtrs
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$3.74B	USD	2 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$112.00M	USD	2 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$109.00M	USD	2 Qtrs
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-315.00M	USD	2 Qtrs
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-207.00M	USD	2 Qtrs
Net Cash Provided by (Used in) Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-4.86B	USD	2 Qtrs
Net Cash Provided by (Used in) Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$1.70B	USD	2 Qtrs
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-364.00M	USD	2 Qtrs
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-6.00M	USD	2 Qtrs
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$1.59B	USD	2 Qtrs
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-7.06B	USD	2 Qtrs
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $79 and $71 at January 1, 2023 and 2022, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$9.75B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $79 and $71 at January 1, 2023 and 2022, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.77B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $79 and $71 at January 1, 2023 and 2022, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$5.71B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $79 and $71 at January 1, 2023 and 2022, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.17B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $52 and $78 at June 30, 2023 and 2022, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$9.75B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $52 and $78 at June 30, 2023 and 2022, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.77B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $52 and $78 at June 30, 2023 and 2022, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$5.71B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $52 and $78 at June 30, 2023 and 2022, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.17B	USD	Point-in-time

Comprehensive Income 24 line items

Line Item	Tag	Value	Unit	Period
Net (Loss) Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$-5.97B	USD	1 Quarter
Net (Loss) Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$8.25B	USD	2 Qtrs
Net (Loss) Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$3.94B	USD	1 Quarter
Net (Loss) Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$-3.15B	USD	2 Qtrs
Net unrealized gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$12.00M	USD	2 Qtrs
Net unrealized gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$246.00M	USD	2 Qtrs
Net unrealized gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$183.00M	USD	1 Quarter
Net unrealized gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$145.00M	USD	1 Quarter
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$-278.00M	USD	2 Qtrs
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$-246.00M	USD	1 Quarter
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$25.00M	USD	1 Quarter
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$75.00M	USD	2 Qtrs
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-137.00M	USD	1 Quarter
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-69.00M	USD	2 Qtrs
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-387.00M	USD	1 Quarter
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-422.00M	USD	2 Qtrs
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-132.00M	USD	2 Qtrs
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$102.00M	USD	2 Qtrs
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-17.00M	USD	1 Quarter
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$42.00M	USD	1 Quarter
Comprehensive (Loss) Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$-5.99B	USD	1 Quarter
Comprehensive (Loss) Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$8.36B	USD	2 Qtrs
Comprehensive (Loss) Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$3.99B	USD	1 Quarter
Comprehensive (Loss) Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$-3.29B	USD	2 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.